Evaxion Entered into a Collaboration Agreement with Afrigen Biologics to Develop Novel mRNA Vaccines for Gonorrhea
Shots:
- Under the terms of the agreement, Afrigen Biologics received the exclusive rights to develop & commercialize mRNA vaccines identified by leveraging Evaxion’s EDEN platform across LMICs and African territories
- The collaboration will also access WHO & Medicines Patent Pool’s mRNA Vaccine Technology Transfer Hub for the development of mRNA vaccines. Additionally, preclinical data depicted that EDEN-discovered antigens pertained high level of protection
- EDEN is an AI platform that has the potential to rapidly identify the antigens triggering a robust & highly protective immune response against bacterial infectious disease. Moreover, the collaboration expects to bring additional partners
Ref: Globenewswire | Image: Evaxion
Related News:- Arcturus Collaborated with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
